Open an account

Minerva Neurosciences

NERV · NASDAQ

$2.53+$0.21 (+9.05%)TodayMarket closed ·
Prev close $2.32

About NERV

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The company is headquartered in Waltham, Massachusetts and currently employs 7 full-time employees. The company went IPO on 2014-06-25. The firm is involved in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and has exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson’s disease. The company has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of major depressive disorder (MDD). Seltorexant is an innovative selective orexin 2 receptor antagonist. Its Roluperidone is a compound that has been shown to block serotonin, sigma, and α-adrenergic receptors that are involved in the regulation of mood, cognition, sleep and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A.

Employees
7
Headquarters
Waltham, Massachusetts
Listed
Jun 25, 2014
Sector
Health Care
Industry
Biotechnology
Website
minervaneurosciences.com

NERV key statistics

Market cap
120.80M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
121.03K
Volume
194.29K
Open price
$2.33
High today
$2.59
Low today
$2.32
52 Week high
$12.46
52 Week low
$2.24

Minerva Neurosciences (NERV) at a glance

Minerva Neurosciences (NERV) last traded at $2.53, with a market cap of 120.80M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $2.32 and $2.59. The current price is 9.1% above the day's low and 2.3% below its high.

Volume so far is 194.29K shares, above the average of 121.03K shares a day.

Over the past year Minerva Neurosciences has ranged from $2.24 to $12.46, and now sits 3% of the way up that range.

Minerva Neurosciences met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.17 per share against an estimate of -$0.1394.

The average analyst price target is $10.54, 316.6% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

67%of 3 analyst ratings say Buy
  • Buy66.7%
  • Hold33.3%
  • Sell0.0%
Price target · 5 analystsAvg $10.54
Low
$7.07
Now
$2.53
High
$14.70

NERV earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 50.7% on average.

  1. Q2 FY24: reported -$1.09 per share against an estimate of -$0.9894
  2. Q3 FY24: reported -$0.54 per share against an estimate of -$1.03
  3. Q4 FY24: reported -$0.56 per share against an estimate of -$1.07
  4. Q1 FY25: reported -$0.50 per share against an estimate of -$1.09
  5. Q2 FY25: reported -$0.43 per share against an estimate of -$0.918
  6. Q4 FY25: reported -$0.64 per share against an estimate of -$0.306
  7. Q1 FY26: reported -$0.17 per share against an estimate of -$0.1292
  8. Q2 FY26: reported -$0.17 per share against an estimate of -$0.1394

NERV news

  • 12 Health Care Stocks Moving In Monday's After-Market Session

  • Avi Kapoor

    US Stocks Mixed; Coca-Cola Posts Upbeat Earnings

  • 12 Health Care Stocks Moving In Thursday's After-Market Session

Similar companies

Companies in the same industry as Minerva Neurosciences

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.